#simulation based training - recommendations on how to classify basic / intermediate / advanced skills training

New publication in MITAT The Optimal Laser Fiber Core Size in Endourology – A Systematic Review https://t.co/SIk5rdm8Em @dratozsin @SelcukGuven_8 @kahmed198 @Urologeman

Our new paper in Minerva Urology and Nephrology “Impact of Minimally Invasive Surgical Therapies on Sexual Function in Benign Prostatic Hyperplasia – A Systematic Review” @drburakakgul @abdullatif_aydn @omeronurcakir @dratozsin @noel_onika @drbalasar @proflutfitunc

Durability of minimally invasive BPH therapies varies widely across techniques, and industry involvement remains a major source of bias. Our new systematic review: https://t.co/i2PvBA3ayr @drburakakgul @dratozsin @abdullatif_aydn @TheodorosTokas @dr_romero_otero

Great to finally get the MIND-P study published. Highlights the importance of mental wellbeing in prostate cancer and prognostic factors for poorer outcomes. @prokarurol @kahmed198 https://t.co/KSvITyoiOo

We’ve summarized evidence from the ROBUST trials on #Optilume to highlight when paclitaxel-coated balloon dilation for #urethralstricture works, needs caution, or should be avoided. Read more: https://t.co/HlCJ3ddvEQ @EurUrolFocus @Uroweb @EAUYAUrology

Residual stone fragments here to stay! Our new analysis and risk classification, published in @wjurol, proposes high, intermediate, and low-risk RSF to inform treatment and research. Access the full text with @Tubitak Open Access support. https://t.co/BhFUvvOAKz @kahmed198

Unique Urolithiasis Challenges: We address the complexities of #urolithiasis in children with neurological disorders, focusing on key risk factors—immobilization, UTIs, and effective treatment strategies. Just published in @wjurol @dratozsin @kahmed198

Standing on FURM Ground: A Framework for Evaluating Fair, Useful, and Reliable AI Models in Health Care Systems: https://t.co/5NcUsFkCY6

Excited to announce our collaborative research with @MeramUrology_ and @Urology_KCH, led by @SelcukGuven_8 and @kahmed198, is now published in @wjurol. I’m grateful to my mentors for their invaluable support and guidance on my first paper as lead author. https://t.co/k81QCyqjIH

A unique session where young urologists and residents engage directly with leading experts! @URAI_8 #URAI24 #YoungUrologists #UrologyRevolution

How accurate & ethical are claims of #ArtificialIntelligence outperforming clinicians? "Constructive ethical guidance that can benefit authors, journal editors, & peer reviewers when reporting and evaluating findings in studies comparing AI to physician performance" is offered

Young Urologists&Residents Panel with Experts at #URAI 📅10 Oct 2024 📍Altınel-Ankara Hotel&Convention Centre ⏰17.30 - 18.30 👉 https://t.co/n8E316raXU @NicholasRaison @kahmed198 @TheodorosTokas @omeronurcakir @erenerl_ @FGuldibi @dinowhassan @harun_ucmak

#Metaverse #ArtificialIntelligence #Sustainability and #Humanfactor Urologists' perspective😷The time has come to keep up with the changing era. Keep updated🦾 #URAI https://t.co/n8E316rINs @Urologeman @kahmed198 @RassweilerJens @NicholasRaison @UroScript @WU_forum @cca_forum

Nearly half of dementia cases could be prevented or delayed by tackling 14 risk factors starting in childhood, including two new risks—high cholesterol and vision loss, suggests new report from the Lancet Commission on dementia. Find out more ➡️ https://t.co/FmfDSNfQ9f

JAMA Clinical Guidelines Synopsis summarizes the @accpchest 2022 guideline on perioperative management of patients taking oral anticoagulation or antiplatelet therapy who are undergoing an elective surgery or procedure. https://t.co/RRfIEtm4Uq

Review Article: Medical Artificial Intelligence and Human Values https://t.co/DbRW8CeLJd #AIinMedicine

🧵 New Special Communication examines drawing causal inferences about the effects of interventions from observational studies in medical journals and suggests a framework that might be used. https://t.co/2KoFti2nQl

Medical News in Brief: Prostate Cancer Cases Might Rise to 3 Million Globally By 2040

Ignore the minds of your #ProstateCancer patients at your peril! Key message at #AUA24 from @BrunckhorstO @kahmed198 @kingshealth & colleagues from 8UK centres from @KingsMINDU group 45% have mental health issues 8% suicidal Risk factors = Younger age Prior psychiatric h/o

The anti–programmed death 1 antibody pembrolizumab was approved by the @US_FDA as adjuvant therapy after surgery for renal-cell carcinoma on the basis of improvements in disease-free survival observed in KEYNOTE-564. Data on overall survival are needed. https://t.co/oVQXvyffL4